Clinical responses to sildenafil in Waldenstrom's macroglobulinemia

Clinical Lymphoma

Volumn 5, Issue 3, 2004, Pages 205-207

  Treon, Steven P ^a   Tournilhac, Olivier ^a   Branagan, Andrew R ^a   Hunter, Zachary ^a   Xu, Lian ^a   Hatjiharissi, Evdoxia ^a   Santos, Daniel D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Lymphoplasmacytic lymphoma; Phosphodiesterase inhibitor

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; CLADRIBINE; CLOPIDOGREL; ERYTHROPOIETIN; IMMUNOGLOBULIN M; PHOSPHODIESTERASE; SILDENAFIL;

ADULT; AGED; APOPTOSIS; B LYMPHOCYTE; BONE MARROW BIOPSY; CANCER REGRESSION; CELL CULTURE; CLINICAL ARTICLE; CULTURE MEDIUM; DRUG MECHANISM; DRUG RESPONSE; ERECTILE DYSFUNCTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NOSE CONGESTION; REVIEW; TREATMENT OUTCOME; TUMOR CELL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 13644263829     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.029     Document Type: Article

References (5)

1. Moon E, Lee R, Near R, et al. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin Cancer Res 2002; 8:589-595.
2. Sarfati M, Mateo V, Baudet S, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003; 101:265-269.
3. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol 2003; 30:110-115.
4. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:127-131.
5. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53(suppl 1):5S-12S.